CIMAvax-EGF: Cuba's Therapeutic Lung Cancer Vaccine

1. Summary

CIMAvax-EGF is a therapeutic cancer vaccine developed by the Center for Molecular Immunology (CIM) in Havana, Cuba, and approved for use in Cuba since 2011 as switch maintenance therapy for advanced non-small cell lung cancer (NSCLC). The vaccine operates through an active immunotherapy mechanism: it induces polyclonal antibodies against autologous epidermal growth factor (EGF), depleting circulating EGF and thereby starving EGF-dependent tumor cells. This mechanism is mechanistically distinct from small-molecule tyrosine kinase inhibitors and monoclonal antibodies, and it offers potential applicability across EGFR mutation statuses.

The pivotal phase III randomized controlled trial (N=405) demonstrated a median survival time of 10.83 months in the vaccine arm versus 8.86 months in the control arm. In patients with high baseline EGF concentrations, the hazard ratio favoured CIMAvax-EGF at 0.44 (p=0.000). However, these results are contested: the trial was open-label, and the non-proportionality of hazards has raised questions about the appropriateness of conventional survival analyses. More than 5,000 patients have been treated with the vaccine in real-world settings, and phase IV studies have confirmed its safety and feasibility of administration in primary-care settings.

Economically, CIMAvax-EGF is reported to cost approximately USD 1 per shot to manufacture, a figure that, if verified, would represent a dramatic cost advantage over checkpoint inhibitors and other NSCLC therapies. The vaccine is currently approved in Cuba and seven other countries (Argentina, Bosnia and Herzegovina, Colombia, Kazakhstan, Paraguay, Peru, and Belarus), but it remains unavailable outside clinical trials in the United States and has not received European Medicines Agency approval. The Innovative Immunotherapy Alliance SA joint venture between CIM and Roswell Park Comprehensive Cancer Center, established in 2018 and operating out of Cuba's Special Development Zone of Mariel, represents the principal pathway for U.S. clinical development.

The most material risks include: (1) clinical uncertainty regarding the magnitude and durability of survival benefit in larger, more diverse populations; (2) regulatory barriers in high-income countries, particularly the United States and the European Union; (3) geopolitical fragility of the U.S.-Cuba collaboration, which is dependent on the broader bilateral relationship; and (4) supply chain vulnerabilities, including dependence on specialized adjuvants.

Strategic recommendations: For health policymakers in middle-income countries, the report recommends considering CIMAvax-EGF as a cost-effective maintenance therapy option, investing in technology transfer and local production capacity, and supporting rigorous post-market surveillance. For U.S. and EU regulators, the report recommends establishing clear pathways for the use of foreign clinical data, facilitating regulatory dialogue with CECMED, and considering expedited review mechanisms for therapies with compelling cost-effectiveness profiles.

2. Contextual and Scientific Background

2.1. The Burden of Non-Small Cell Lung Cancer (NSCLC)

Lung cancer is the leading cause of cancer-related mortality globally. According to the World Health Organization, there were an estimated 2.5 million new cases and 1.8 million deaths from lung cancer in 2022. NSCLC accounts for approximately 85 percent of all lung cancer cases. These figures are derived from the Global Burden of Disease study and WHO cancer registries; they are modelled estimates based on reported incidence and mortality data.

Despite advances in treatment, the prognosis for advanced NSCLC remains poor. Five-year survival rates for stage IIIB/IV disease are typically below 5 percent with conventional chemotherapy. The limitations of existing therapeutic modalities are well documented. Cytotoxic chemotherapy offers modest survival benefits with significant toxicity. Targeted therapies, tyrosine kinase inhibitors such as gefitinib and erlotinib, are effective only in the subset of patients, approximately 10 to 15 percent in Caucasian populations and higher in Asian populations, whose tumors harbor activating EGFR mutations. Checkpoint inhibitors such as nivolumab and pembrolizumab have improved outcomes but are expensive, require biomarker selection in many cases, and are associated with immune-related adverse events. There remains a substantial unmet need for safe, effective, and affordable therapies applicable to the broad population of NSCLC patients, including those without targetable mutations.

2.2. The EGF/EGFR Axis as a Therapeutic Target
The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor that plays a central role in cellular proliferation, survival, angiogenesis, and metastasis. Overexpression of EGFR is observed in a significant proportion of NSCLC tumors and is associated with uncontrolled proliferation, anti-apoptotic signaling, and invasiveness.

CIMAvax-EGF targets this axis through a mechanism fundamentally distinct from small-molecule tyrosine kinase inhibitors and monoclonal antibodies. The vaccine consists of recombinant human EGF conjugated to a carrier protein (rP64K, derived from Neisseria meningitidis) and emulsified in Montanide ISA 51 adjuvant. It induces active immunotherapy: the patient's immune system generates polyclonal antibodies against autologous EGF, which neutralize circulating EGF and deplete it from the bloodstream. This EGF withdrawal starves EGF-dependent tumor cells of a key growth signal [1][8].

The significance of this mechanism lies in its potential applicability across EGFR mutation statuses. Unlike TKIs, which require specific activating mutations in the EGFR kinase domain for efficacy, CIMAvax-EGF's mechanism is independent of tumor EGFR mutation status. It targets the ligand rather than the receptor, and it operates systemically by reducing the availability of EGF in the circulation and tumour microenvironment. This makes it theoretically applicable to a broader patient population, including those with wild-type EGFR who are ineligible for TKI therapy.

2.3. Development History and Clinical Trial Program
The development of CIMAvax-EGF began at the Center for Molecular Immunology in Havana in the mid-1990s. Preclinical studies established the immunogenicity and safety of the EGF-P64K conjugate. Early-phase trials (phase I/II) conducted in Cuba demonstrated that the vaccine was safe and capable of inducing antibody responses against EGF [9].

The formulation was optimized through the use of the P64K carrier protein from Neisseria meningitidis and the Montanide ISA 51 adjuvant. The P64K protein enhances the immunogenicity of the EGF antigen, while Montanide ISA 51 acts as a water-in-oil emulsion adjuvant that promotes a sustained antibody response [8][12].

The pivotal phase III randomized controlled trial, published in 2016, enrolled 405 patients with advanced (stage IIIB/IV) NSCLC who had completed four to six cycles of platinum-based chemotherapy. Patients were randomized to receive CIMAvax-EGF or best supportive care as switch maintenance therapy. The trial was open-label and multicentric. In the safety population (intention-to-treat analysis), median survival time was 10.83 months in the vaccine arm versus 8.86 months in the control arm. In the per-protocol analysis, patients receiving at least four vaccine doses, survival was significantly longer in the vaccine arm. High baseline EGF concentration was identified as a predictive biomarker of vaccine activity and a poor prognostic biomarker in untreated patients. In the high-EGF subgroup, the hazard ratio favoured CIMAvax-EGF at 0.44 (p=0.000) [10].

However, the trial results are contested. The open-label design introduces potential bias. More significantly, the non-proportionality of hazards, the survival curves diverged only after several months, has raised questions about the appropriateness of conventional log-rank tests and Cox proportional hazards models. Some analysts have argued that the statistical methods used may have overestimated the treatment effect. These are not merely technical quibbles; they bear directly on the regulatory acceptability of the trial data in jurisdictions with stringent evidentiary standards.

Following the phase III trial, a phase IV study was conducted in which the vaccine was administered in primary care units across Cuba. This real-world evidence study, involving 741 patients, confirmed the safety of the vaccine and demonstrated the feasibility of administration in community polyclinic settings. Median overall survival in this real-world cohort ranged from 9.9 to 12 months depending on disease stability post-induction [0][5].

Clinical trials have also been conducted outside Cuba. Serbia's Institute of Virology, Vaccines and Sera (Torlak Institute) signed a memorandum in October 2015 for use in 30 patients. The most significant external development has been the clinical trial program at Roswell Park Comprehensive Cancer Center in Buffalo, New York, which received FDA Investigational New Drug approval in October 2016 [14][7]. A phase I trial of CIMAvax-EGF in combination with nivolumab (an anti-PD-1 checkpoint inhibitor) was initiated in 2017. The combination was determined to be safe and tolerable, with a recommended phase II dose of 2.4 mg. Humoral response to CIMAvax-EGF was achieved earlier and in a greater number of patients with the combination compared to historical controls. Four out of 12 evaluable patients had an objective response. These findings are preliminary and derive from a small phase I study; they should be interpreted with appropriate caution [7].

3. Key Players and Stakeholders

3.1. Center for Molecular Immunology (CIM), Havana

The Center for Molecular Immunology (Centro de Immunologia Molecular, CIM) is the developer and manufacturer of CIMAvax-EGF. Founded in the early 1990s, CIM is a premier biomedical research institution in Cuba, operating under the state holding company Biocubafarma. CIM's mandate encompasses the discovery, development, and production of innovative biologics, with a particular focus on cancer immunotherapies and monoclonal antibodies. The center holds the Cuban sanitary registration for CIMAvax-EGF and has patented the vaccine in multiple jurisdictions, including Canada, the United States, Japan, and South Africa. CIM's position within Cuba's biotechnology sector is central: it is one of the flagship institutions of the Cuban biotech industry and a key contributor to the country's portfolio of innovative health technologies [6][12].

3.2. Roswell Park Comprehensive Cancer Center, Buffalo, New York
Roswell Park Comprehensive Cancer Center is the sole U.S. institution with FDA Investigational New Drug approval to conduct clinical trials of CIMAvax-EGF [11][13][4]. The collaboration originated in 2015, following a trade delegation to Cuba led by New York Governor Andrew Cuomo [13]. In 2017, Roswell Park initiated clinical trials of CIMAvax-EGF, initially in combination with nivolumab. The Roswell Park Alliance Foundation committed USD 4 million in donor funds to cover the cost of the initial clinical trials. In 2018, Roswell Park and CIM established the joint venture Innovative Immunotherapy Alliance SA, operating out of Cuba's Special Development Zone of Mariel. This joint venture represents the principal institutional mechanism for the clinical development and potential commercialization of CIMAvax-EGF in the United States [6][5].

3.3. Biocubafarma and the Cuban Biopharmaceutical Industry
CIMAvax-EGF is situated within the broader Cuban biopharmaceutical sector, which is organized under the state holding company Biocubafarma. The sector has a strategic importance to the Cuban economy, representing one of the country's most significant exports and a source of scientific prestige. Despite resource constraints and the U.S. embargo, Cuba has developed a robust biotechnology industry, producing innovative biologics including therapeutic vaccines, monoclonal antibodies, and interferons. CIMAvax-EGF is emblematic of this capability: it is a first-in-class therapeutic vaccine developed entirely in a middle-income country under conditions of economic isolation.

3.4. Regulatory Agencies
The relevant regulatory bodies include Cuba's Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos (CECMED), which granted sanitary registration to CIMAvax-EGF in 2011. In the United States, the FDA granted Investigational New Drug approval in October 2016 but has not approved the vaccine for commercialization. The vaccine is also approved by regulatory authorities in Argentina, Bosnia and Herzegovina, Colombia, Kazakhstan, Paraguay, Peru, and Belarus. It has not received European Medicines Agency approval [11].

4. Technical and Operational Considerations

4.1. Manufacturing Process and Supply Chain

CIMAvax-EGF is composed of recombinant human epidermal growth factor conjugated to the rP64K carrier protein, emulsified in Montanide ISA 51 adjuvant [12][8]. The manufacturing process involves the production of recombinant EGF and rP64K proteins, chemical conjugation, formulation with the adjuvant, and fill-finish operations. The vaccine is manufactured at CIM's facilities in Havana.

The supply chain has several potential vulnerabilities. The Montanide ISA 51 adjuvant is a proprietary product manufactured by Seppic (France), introducing a dependence on a single supplier and potential exposure to international sanctions or trade disruptions. The recombinant proteins require specialized production equipment and quality control systems. However, CIM has demonstrated the capacity to manufacture the vaccine at scale for the Cuban national health system and for export.

The reported manufacturing cost of approximately USD 1 per shot is frequently cited. This figure appears in various news reports; no peer-reviewed source providing a detailed cost breakdown was identified for this figure. The basis for this estimate, whether it represents marginal cost, full cost including research and development amortisation, or cost in a Cuban context with subsidised inputs, is not transparent. Nevertheless, even if the true cost is several multiples of this figure, CIMAvax-EGF would remain dramatically less expensive than checkpoint inhibitors, which typically cost tens of thousands of dollars per course. The implications for affordability and scalability are substantial, particularly in resource-constrained health systems [3].

4.2. Storage, Distribution, and Administration

CIMAvax-EGF is reported to be relatively cheap to store. Specific data on cold-chain requirements and room-temperature stability were not identified in the available sources; this represents a gap in the publicly available evidence base.

The administration regimen consists of an induction phase (initial doses) followed by a maintenance phase (booster doses). The vaccine is administered intramuscularly. In Cuba, administration has been extended to 119 community polyclinics and 24 hospitals, demonstrating the feasibility of delivery in a primary-care setting. This is a significant operational achievement: it indicates that CIMAvax-EGF can be integrated into routine primary care without requiring specialized oncology infrastructure, which has important implications for scalability in low-resource settings [2][0].

4.3. Safety and Adverse Event Profile

The safety data from clinical trials and real-world use indicate that CIMAvax-EGF has a favorable safety profile. Most adverse reactions are grade 1 or 2 and include injection-site pain, fever, chills, headache, and vomiting. No significant immunotoxicity has been reported. In the phase I combination trial with nivolumab, no patient experienced life-threatening side effects attributable to the combination [10][3]. The vaccine has been administered to more than 5,000 patients. However, long-term safety data are limited; no peer-reviewed source was identified providing systematic long-term follow-up beyond the clinical trial periods [12].

5. Economic and Market Dynamics

5.1. Pricing

The pricing strategy in different markets is not publicly documented; in Cuba, the vaccine is provided free of charge through the national health system [3].

5.2. Cost-Effectiveness and Health Economic Analyses

Published cost-effectiveness studies of CIMAvax-EGF are limited. A costing procedure for the vaccine has been described, but no peer-reviewed cost-effectiveness analysis comparing CIMAvax-EGF to standard of care in different health system contexts was identified in the available sources [3]. This represents a significant gap in the evidence base. Given the vaccine's low reported cost and favorable safety profile, it has the potential to offer a highly cost-effective maintenance therapy in resource-constrained health systems, particularly in low- and middle-income countries. However, formal health economic evaluations are needed to substantiate this claim.

5.3. Market Access and Commercialization

The barriers to market access in high-income countries are substantial. In the United States, the FDA requires rigorous clinical trial data meeting U.S. standards, including randomized controlled trials with appropriate endpoints, statistical methods, and Good Clinical Practice compliance. The Cuban clinical trial data, while informative, may not meet FDA evidentiary standards due to the open-label design, questions about statistical methods, and the absence of U.S.-standard trial monitoring. The Roswell Park trials are designed to address these gaps, but they are at an early stage (phase I completed; further trials pending). In the European Union, the EMA similarly requires comprehensive clinical data meeting European standards; no application has been submitted [4].

The commercial potential if FDA or EMA approval were obtained is considerable. The global NSCLC maintenance therapy market is substantial, and a safe, effective, low-cost immunotherapy would have significant market appeal, particularly if priced competitively. However, the commercialization pathway is uncertain and depends on the successful completion of clinical trials, regulatory approval, and the resolution of geopolitical barriers.

5.4. Intellectual Property and Technology Transfer

CIMAvax-EGF has been patented in Cuba, Canada, the United States, Japan, and South Africa, among other countries. The patent holder is CIM (through its commercial entity CIMAB S.A.). The enforceability of these patents in key jurisdictions depends on the strength of the patent claims and the absence of prior art; no information on patent challenges or litigation was identified in the available sources.

Technology transfer has occurred through the Innovative Immunotherapy Alliance SA joint venture, established in 2018 between CIM's commercial arm and Roswell Park. The joint venture is based in Cuba's Special Development Zone of Mariel and includes CIMAvax-EGF among its products. The joint venture's stated objective is to conduct clinical research to demonstrate the safety and effectiveness of Cuban-developed immunotherapies to U.S. regulatory standards. The implications for intellectual property and commercialization are significant: the joint venture provides a mechanism for Roswell Park to access CIM's technology and for CIM to access U.S. clinical development and commercialization expertise. However, the joint venture's operations are dependent on the broader U.S.-Cuba bilateral relationship and may be vulnerable to political changes [6][5].

6. Regulatory

6.1 Barriers and Pathway

Potential pathways to approval include: (1) the continued clinical development through the Roswell Park-CIM collaboration, leading to a Biologics License Application (BLA) to the FDA; (2) the use of foreign clinical data (from Cuban and other international trials) to supplement U.S. trial data, under FDA's acceptance of foreign clinical data policies; (3) the pursuit of an Orphan Drug designation or other expedited review mechanisms; and (4) the potential for the joint venture to facilitate regulatory dialogue and data sharing. However, these pathways are uncertain and depend on political as well as scientific and regulatory factors [11][4].

7. Geopolitical and Strategic Dimensions

7.1. CIMAvax-EGF as a Symbol of Cuban Scientific Capacity

CIMAvax-EGF exemplifies Cuba's investment in biotechnology and its ability to produce innovative therapies despite economic constraints and the U.S. embargo. The vaccine is a first-in-class therapeutic cancer vaccine developed entirely in a middle-income country, a significant scientific achievement. It represents a form of "soft power" for Cuba, demonstrating the country's scientific and technological capabilities on the international stage. The vaccine has been presented as evidence of what a socialist health system can achieve under conditions of economic isolation. For Cuba, CIMAvax-EGF is not merely a therapeutic product but a symbol of national scientific sovereignty and a tool of diplomatic engagement.

7.2. U.S.-Cuba Scientific Collaboration
The Roswell Park-CIM collaboration is a rare instance of U.S.-Cuba cooperation in the health sector. The collaboration originated during the Obama-era détente, following the 2015 trade delegation led by New York Governor Andrew Cuomo [13]. The establishment of the Innovative Immunotherapy Alliance SA joint venture in 2018 represented a historic first in U.S.-Cuba biotech cooperation. However, the collaboration is fragile and dependent on the broader bilateral relationship. The Trump administration imposed restrictions on travel and trade with Cuba, and while the Biden administration has partially reversed some measures, the overall relationship remains fraught. The collaboration's continuation is uncertain and could be disrupted by changes in U.S. policy. The joint venture's operations, including the conduct of clinical trials and the potential commercialization of CIMAvax-EGF, are contingent on the maintenance of the bilateral cooperation framework [6][5].

7.3. Implications for Global Health Equity
CIMAvax-EGF's low cost and favorable safety profile make it a candidate for widespread use in low- and middle-income countries, where access to expensive checkpoint inhibitors and targeted therapies is severely limited. The vaccine could potentially address a significant global disparity in access to cancer therapeutics. However, several challenges must be addressed: (1) technology transfer to enable local production in other countries; (2) regulatory harmonisation to facilitate approval in multiple jurisdictions; (3) financing mechanisms to support procurement and distribution in resource-constrained settings; and (4) the generation of additional clinical evidence in diverse populations to confirm efficacy and safety. The World Health Organization's prequalification programme could potentially play a role in facilitating access, but no information on WHO engagement with CIMAvax-EGF was identified in the available sources.

7.4. Strategic Competition and Biopharmaceutical Sovereignty
CIMAvax-EGF can be understood as an instance of "biopharmaceutical sovereignty", a country's capacity to develop and produce its own essential medicines, independent of multinational pharmaceutical companies and global supply chains. For middle-income countries seeking to build indigenous biotech capacity, CIMAvax-EGF offers a model: a government-supported research institution, operating with limited resources, developing a first-in-class therapeutic product through a sustained program of basic and clinical research. The implications for other middle-income countries are significant: CIMAvax-EGF demonstrates that it is possible to develop innovative biologics outside the traditional centers of pharmaceutical innovation, provided there is sustained political commitment, scientific capacity, and investment in research infrastructure.

8. Risk Matrix

9. Strategic Recommendations

9.1. Recommendations for Health Policymakers in Middle-Income Countries

1. Consider CIMAvax-EGF as a cost-effective maintenance therapy option. The vaccine's low reported cost and favourable safety profile make it an attractive option for resource-constrained health systems. Policymakers should commission formal health economic evaluations specific to their national contexts to assess the cost-effectiveness of CIMAvax-EGF compared to current standard of care.
2. Invest in technology transfer and local production capacity. To ensure sustainable access and reduce dependence on imports, middle-income countries should explore technology transfer agreements with CIM, enabling local production of the vaccine. This would require investment in manufacturing infrastructure, quality control systems, and regulatory capacity.
3. Support rigorous post-market surveillance. If CIMAvax-EGF is adopted, countries should establish comprehensive post-market surveillance systems to monitor real-world effectiveness and safety, contributing to the global evidence base.
4. Engage in regulatory harmonisation efforts. To facilitate approval and access, policymakers should work toward regulatory harmonisation within regional blocs, potentially through mutual recognition agreements or joint review mechanisms.
5. Explore combination strategies in clinical practice. Given the preliminary evidence of synergistic effects with checkpoint inhibitors, policymakers should consider supporting clinical trials of combination regimens within their national health systems.

9.2. Recommendations for U.S. and EU Regulators

1. Establish clear pathways for the use of foreign clinical data. Regulators should develop and communicate clear guidelines on the acceptability of foreign clinical data, including data from Cuban trials, to support regulatory submissions. This would reduce uncertainty and facilitate the development pathway.
2. Facilitate regulatory dialogue with CECMED. Regulators should engage in technical dialogue with Cuba's CECMED to understand the basis of the Cuban registration and to identify areas where additional data may be required for U.S. or EU approval. Such dialogue could also support mutual learning and regulatory capacity building.
3. Consider expedited review mechanisms. Given the potential public health benefit of a safe, low-cost NSCLC therapy, regulators should consider whether CIMAvax-EGF is eligible for expedited review pathways, such as Breakthrough Therapy designation (FDA) or PRIME (EMA), if the clinical data warrant.
4. Support the clinical trial programme. Regulators should provide timely and constructive feedback on clinical trial designs for CIMAvax-EGF, including combination studies, to ensure that the trials generate the data needed for regulatory decisions.
5. Monitor geopolitical developments and maintain contingency plans. Given the geopolitical fragility of the U.S.-Cuba collaboration, regulators should maintain awareness of the political context and be prepared to adapt regulatory approaches if the collaboration is disrupted.

Why Are There No Approved iPSC Therapies in 2026? Manufacturing and Reimbursement Explained

Twenty years after iPSCs were invented, no therapy is approved in the US or EU. The fight now is manufacturing cost and reimbursement, not science.

DataDeep TechMarcus Hale

References

[1] Crombet Ramos T, et al. "CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer." Expert Rev Vaccines. 2015;14(10):1303-11.

[2] Rodríguez PC, et al. "Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy." MEDICC Rev. 2010;12(1):17-23.

[3] Saavedra D, et al. "CIMAvax-EGF: Toward long-term survival of advanced NSCLC." Semin Oncol. 2018;45(1-2):34-40.

[4] Rodriguez PC, et al. "A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients." Clin Cancer Res. 2016;22(15):3782-90.

[5] Roswell Park Comprehensive Cancer Center. "CIMAvax Lung Cancer Vaccine." Buffalo, NY.

[6] Centro de Inmunología Molecular. "CIMAvax-EGF." Havana, Cuba.

[7] Associated Press. "Roswell Park to conduct trial of Cuban lung cancer treatment." 2016.

[8] Evans RR, et al. "Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC." Front Oncol. 2022;12:958043.

[9] World Health Organization. "Lung cancer." Geneva. 2022.

[10] Saavedra D, et al. "CIMAvax-EGF: Toward long-term survival of advanced NSCLC." Semin Oncol. 2018;45(1-2):34-40.

[11] Crombet Ramos T, et al. "CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer." Expert Rev Vaccines. 2015;14(10):1303-11.

[12] Centro de Inmunología Molecular. "CIMAvax-EGF." Havana, Cuba.

[13] Associated Press. "Roswell Park to conduct trial of Cuban lung cancer treatment." 2016.

[14] Evans RR, et al. "Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC." Front Oncol. 2022;12:958043.